Trabectedin's contribution to the treatment of sarcomasBLAY, Jean-Yves.Expert review of anticancer therapy. 2013, Vol 13, Num 6, pp 3-9, issn 1473-7140, 7 p., SUP1Article

[A decade of change in the treatment of advanced soft tissue sarcoma]BLAY, Jean-Yves.Expert review of anticancer therapy. 2013, Vol 13, Num 6, issn 1473-7140, [29 p.], SUP1Serial Issue

Les enjeux de la recherche clinique sur les tumeurs rares en Europe = Challenges for clinical research on rare tumors in EuropeBLAY, Jean-Yves.Bulletin de l'Académie nationale de médecine. 2013, Vol 197, Num 1, pp 103-122, issn 0001-4079, 20 p.Article

Les thérapeutiques ciblées du cancer : not lost in translation : Cent ans d'innovations diagnostiques et thérapeutiques en cancérologie = Targeted therapies of cancer : not lost in translationBLAY, Jean-Yves.Bulletin du cancer. 2006, Vol 93, Num 8, pp 799-804, issn 0007-4551, 6 p.Article

Gastrointestinal stromal tumors: Biology and treatmentDUFFAUD, Florence; BLAY, Jean-Yves.Oncology. 2003, Vol 65, Num 3, pp 187-197, issn 0030-2414, 11 p.Article

Cytokines de nouvelle génération pour prévenir l'anémie et la neutropénie fébrile : Facteurs de croissance hématopoïétique : nouvelles modalités d'utilisation = New generation cytokines to prevent anemia and febrile neutropeniaFAYETTE, Jérome; BLAY, Jean-Yves.Bulletin du cancer. 2006, Vol 93, Num 5, pp 483-488, issn 0007-4551, 6 p.Article

Adherence to imatinib therapy in patients with gastrointestinal stromal tumorsBLAY, Jean-Yves; RUTKOWSKI, Piotr.Cancer treatment reviews. 2014, Vol 40, Num 2, pp 242-247, issn 0305-7372, 6 p.Article

Current questions in soft tissue sarcoma: further steps with Yondelis^®REICHARDT, Peter.Expert review of anticancer therapy. 2013, Vol 13, Num 6, pp 25-32, issn 1473-7140, 8 p., SUP1Article

EORTC 1962-2012: 50 Years of Progress Against CancerBLAY, Jean-Yves; MEUNIER, Françoise.European journal of cancer. Supplement (1990). 2012, Vol 10, Num 1, issn 1359-6349, 171 p.Serial Issue

Inhibition de IGF-1R et sarcomesMASSARD, Christophe; BLAY, Jean-Yves.Bulletin du cancer. 2010, Vol 97, Num 8, issn 0007-4551, p. 895Article

La chimiothérapie adjuvante des sarcomes = Adjuvant chemotherapy in the treatment of sarcomasFAYETTE, Jérome; BLAY, Jean-Yves.Bulletin du cancer. 2006, Vol 93, Num 3, pp 257-261, issn 0007-4551, 5 p.Article

13 years of trabectedin, 5 years of Yondelis^®: what have we learnt?LE CESNE, Axel.Expert review of anticancer therapy. 2013, Vol 13, Num 6, pp 11-19, issn 1473-7140, 9 p., SUP1Article

Le traitement médical des GIST: du palliatif au curatif = Medical therapy of GIST; from palliative to curative treatmentLE CESNE, Axel; BLAY, Jean-Yves.Bulletin de l'Académie nationale de médecine. 2012, Vol 196, Num 4-5, pp 861-874, issn 0001-4079, 14 p.Conference Paper

Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

Chimiothérapie à hautes doses dans les sarcomes des tissus mous de l'adulte = High-dose chemotherapy in soft tissue sarcomas of adultsRAY-COQUARD, Isabelle; BIRON, Pierre; BLAY, Jean-Yves et al.Bulletin du cancer. 2001, Vol 88, Num 9, pp 858-862, issn 0007-4551Article

Molecular response prediction in gastrointestinal stromal tumors : Special focus: Response prediction: Coordinated by E. Van Cutsem and F. CiardielloCASSIER, Philippe A; BLAY, Jean-Yves.Targeted oncology. 2010, Vol 5, Num 1, pp 29-37, issn 1776-2596, 9 p.Article

De l'eau au moulin de thérapies ciblant l'interleukine-6 dans les tumeurs épithéliales = Interleukin-6 and epithelial tumours : new convincing arguments in favour of the use of IL-6 targeted therapiesGOUGELET, Angélique; MANSUY, Adeline; BLAY, Jean-Yves et al.MS. Médecine sciences. 2008, Vol 24, Num 8-9, pp 694-696, issn 0767-0974, 3 p.Article

Tumeurs stromales gastro-intestinales = Gastro-intestinal stromal tumorsCASSIER, Philippe A; BLAY, Jean-Yves.Hépato-gastro (Montrouge). 2010, Vol 17, Num 1, pp 60-66, issn 1253-7020, 7 p.Article

La thérapie cellulaire pour l'intensification thérapeutique en onco-hématologie :manipulation des greffons de cellules souches périphériques = Cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood stem-cell productsDOUAY, Luc.Bulletin du cancer. 2001, Vol 88, Num 9, pp 826-832, issn 0007-4551Article

Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?ADENIS, Antoine; PENEL, Nicolas; BLAY, Jean-Yves et al.Oncology. 2009, Vol 77, Num 3-4, pp 157-161, issn 0030-2414, 5 p.Article

TRAITEMENT ADJUVANT DU CANCER DU SEIN ET THÉRAPIE CIBLÉE : L'ajout du trastuzumab à la chimiothérapie adjuvante diminue de 50 % le risque de récidiveDUFRESNE, Armelle; BACHELOT, Thomas; BLAY, Jean-Yves et al.La Revue du praticien (Paris). 2008, Vol 58, Num 5, pp 477-478, issn 0035-2640, 2 p.Article

Greffe de cellules souches sanguinesBAY, Jacques-Olivier; BLAY, Jean-Yves.Bulletin du cancer. 2001, Vol 88, Num 9, issn 0007-4551Serial Issue

The Evolution of a Revolutionary Class: Extending Benefits of Tyrosine Kinase InhibitorsBLAY, Jean-Yves; DEMETRI, George D.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, 35 p., SUP1Serial Issue

Ciblage thérapeutique par l'imatinib mésylate (STI571, Glivec®) à l'Asco 2002 = Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002RAY-COQUARD, Isabelle; BLAY, Jean-Yves.Bulletin du cancer. 2002, Vol 89, Num 6, pp 567-569, issn 0007-4551Article

New fronts in the adjuvant treatment of GISTREICHARDT, Peter; JOENSUU, Heikki; BLAY, Jean-Yves et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 715-723, issn 0344-5704, 9 p.Article